
Beyond the pilot
Great ideas for new digital health solutions are emerging all the time. But too few of them are making the leap from great idea to successful commercial solution at scale.
Biopharmaceuticals face challenges arising from a number of converging trends. It is essential that the function responsible for ensuring that high quality biopharmaceutical medicines reach healthcare professionals, hospitals, and patients in markets, as and when needed – Affiliate Quality (AQ) – is able to keep pace with demands and become a partner to the business.
Our latest white paper explores the role and development of AQ in today’s dynamic industry. By benchmarking ten of the world’s leading biopharmaceuticals, we’ve been able to understand the best practices that are enabling some to generate greater value from AQ, as well as pinpoint the strategic choices that must be made to develop an AQ function that’s fit for purpose in a fast-changing industry.
Great ideas for new digital health solutions are emerging all the time. But too few of them are making the leap from great idea to successful commercial solution at scale.
The growth of digital health solutions has accelerated rapidly in the post-COVID era. But while there are plenty of innovative ideas in development, many companies are still struggling to move beyond promising pilots and into production at scale.
COVID-19 exerted a huge impact on public health in Europe. The virus itself was responsible for a significant rise in premature mortality (between twice to nine-times higher than that of normal seasonal flu). But the at times overwhelming impacts of the pandemic on healthcare systems meant many routine treatments were...
Companies can expect special challenges in pharmaceuticals and life sciences. We'll show you how to master them with a well-planned strategy.
Senior Manager, Customer Transformation, Pharma and Life Sciences, PwC Switzerland
Tel: +41 76 309 92 57